Unió Europea -
noruec -
EMA (European Medicines Agency)
jakavi
novartis europharm limited - ruxolitinib (som fosfat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastiske midler - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi er indisert for behandling av voksne pasienter med polycythaemia vera som er resistente mot eller intolerante av hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.
Noruega -
noruec -
Statens legemiddelverk
rybrila 160 mikrog/ ml
clinigen healthcare b.v. - glykopyrroniumbromid - mikstur, oppløsning med jordbærsmak - 160 mikrog/ ml
Noruega -
noruec -
Statens legemiddelverk
indium [111in] dtpa 37 mbq/ ml
curium netherlands b.v. - indium (111in) pentetat - injeksjonsvæske, oppløsning - 37 mbq/ ml